SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has raised concerns about competition for Precigens PAPZIMEOS and prompted debate over potential sales impact. Traders disagree on whether Inovios treatment could challenge Precigens position or whether PAPZIMEOSs established commercial lead and full approval offer an advantage over the rivals accelerated approval and commercialization hurdles.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons better-than-expected third-quarter results, supported by strong refining performance, are driving attention. Traders are reacting positively to the earnings beat and heavy call activity, while some question whether unusually strong refining margins can last.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 results and stronger-than-expected Q4 profit outlook are driving attention, with traders emphasizing subscriber growth, improving margins, and better ad trends despite revenue and EPS misses. The sharp rise has surprised skeptics, while bulls argue the forward guidance matters more than the quarters headline results.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00385003 USD and is up 3.25 over the last 24 hours. It is currently trading on 374 active market(s) with $20,884,591.23 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

Jasmys announced AppBank collaboration and planned Money Twin personal-AI service are drawing attention alongside a burst of trading activity. Bulls see the partnership and JasmyChain as steps toward real utility, while skeptics argue that adoption and resulting demand for JASMY remain unproven; discussion also centers on volatile price moves and dip buying.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results beat expectations, with strong theme-park performance and improving streaming profitability driving a broadly constructive reaction and renewed analyst optimism. Some traders remain skeptical, pointing to the stocks long-running sluggishness and questioning whether the results can support a sustained re-rating.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.42916419 USD and is up 8.20 over the last 24 hours. It is currently trading on 2313 active market(s) with $611,471,639.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rebound and breakout attempt have sparked bullish momentum and heavy volume, with traders pointing to renewed crypto risk appetite and Chainlinks institutional and tokenization integrations as supportive context. Others warn the move may fade, citing resistance, volatile pullbacks, and doubts that network adoption will translate into lasting value for the LINK token.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,174,495.43496562. The last known price of Ethereum is 2,241.26797415 USD and is down -0.51 over the last 24 hours. It is currently trading on 14214 active market(s) with $20,040,937,711.35 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

The reported record Binance hack is driving concern about crypto exchange security and possible selling pressure across the market, including Ethereum. Traders are split between expecting further downside as confidence and risk appetite weaken and viewing ETHs relative resilience and dip buying as signs the shock may be contained.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is drawing attention as South Korean equities sell off amid an unwind in crowded AI and memory-chip trades, with Samsung and SK Hynix weakness and leveraged positions amplifying volatility. Traders are split between expecting further forced selling and viewing the pullback as a potential buying opportunity.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios Q3 results beat expectations and full-year guidance rose, but shares sold off sharply after its Q4 outlook signaled slower organic growth and messaging deceleration. Traders are debating whether the strong results and potential AI-related demand offset the weaker near-term outlook; many view guidance as the main driver of the drop.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp, high-volume rally has put AMP in focus, though traders point to no confirmed new catalyst. Bulls see a breakout and connect the move to AMPs Flexa collateral role and Anvil developments, while skeptics call it another speculative pump and question whether adoption will translate into meaningful use.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Key PointsAdded 296,944 shares of Trevi Therapeutics; estimated buy value ~$3.32 million based on quarterly average price...

HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday...

Trevi Therapeutics Q1 Earnings Call Highlights

Trevi Therapeutics (NASDAQ:TRVI) management used the company's first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering.

Clinical program updates and upcoming trial starts
Pres...

Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07...

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI

Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...

TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening

Equity

The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?

Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Underwriters were given a 30-day option to purchase up to 1.74 million additional shares.</li><li>Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary fibrosis.</li><li>The company plans to launch two late-stage clinical trials starting in the second quarter of 2026.</li></ul>Shares of Trevi Therapeutics, Inc. (TRVI) jumped 5% on Friday to an all-time high after the biotech firm priced its $150 million underwritten public offering at $13 per share.<a href="https://stocktwits.com/symbol/TRVI">TRVI shares</a> are heading for a fifth consecutive session of gains, rising nearly 20% over the course of the rally.While Trevi offered 11.6 million shares at $13 per share, it also granted underwriters a 30-day option to purchase up to 1.74 million additional shares that could fetch up to $22.5 million. The offering is expected to close around April 20, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier. Message volumes soared a whopping 600% on the platform over the past 24 hours, according to Stocktwits data.One user called the price action “strange” and questioned if it was driven by a “small squeeze.”<stembedurl>https://stocktwits.com/abcdzepeda/message/650605154</stembedurl>Another user, who commented before the $13 per share offer was disclosed, said the dilution seemed unnecessary.<stembedurl>https://stocktwits.com/socalBB/message/650528771</stembedurl><h2 class="st-heading-2">Trevi Prepares To Launch Late-Stage Trials For Chronic Cough Treatment</h2>Trevi Therapeutics is currently developing Haduvio, its treatment for chronic cough in patients with conditions such as idiopathic pulmonary fibrosis, interstitial lung disease, and refractory chronic cough.Last month, the firm <a href="https://stocktwits.com/news-articles/markets/equity/trvi-stock-slips-after-company-plans-parallel-trials-in-lung-disease/cZdVDFCRIeE">announced</a> plans to launch two late-stage clinical trials for Haduvio following discussions with the U.S. Food and Drug Administration (FDA). The first trial is expected to begin in the second quarter of 2026, with the second starting later in the year.Both studies will be randomized and placebo-controlled, testing the drug’s safety and effectiveness. One trial will enroll around 300 patients, while the other will include about 130, Trevi added.The stock has seen heavy buying interest over the past year, surging more than 165%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.56
Prev Close	$13.81
Open	$13.52
Dividend Yield	0.00%
50-Day Moving Average	$14.69
Beta	0.79
Avg. Volume	1.6M
PE Ratio	-39.57

52-Week High	$20.22
52-Week Low	$9.82
Market Capitalization	$1.93B
EPS (Annual)	-$0.3173
Price to Book	6.01
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TRVI Fundamentals